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Abstract
Background: There is little data on the impact of office-based buprenorphine therapy on criminal activity. The
goal of this study was to determine the impact of primary care clinic-based buprenorphine maintenance therapy
on rates of criminal charges and the factors associated with criminal charges in the 2 years after initiation of
treatment.
Methods: We collected demographic and outcome data on 252 patients who were given at least one prescription
for buprenorphine. We searched a public database of criminal charges and recorded criminal charges prior to and
after enrollment. We compared the total number of criminal cases and drug cases 2 years before versus 2 years
after initiation of treatment.
Results: There was at least one criminal charge made against 38% of the subjects in the 2 years after initiation of
treatment; these subjects were more likely to have used heroin, to have injected drugs, to have had any prior
criminal charges, and recent criminal charges. There was no significant difference in the number of subjects with
any criminal charge or a drug charge before and after initiation of treatment. Likewise, the mean number of all
cases and drug cases was not significantly different between the two periods. However, among those who were
opioid-negative for 6 or more months in the first year of treatment, there was a significant decline in criminal
cases. On multivariable analysis, having recent criminal charges was significantly associated with criminal charges
after initiation of treatment (adjusted odds ratio 3.92); subjects who were on opioid maintenance treatment prior
to enrollment were significantly less likely to have subsequent criminal charges (adjusted odds ratio 0.52).
Conclusions: Among subjects with prior criminal charges, initiation of office-based buprenorphine treatment did
not appear to have a significant impact on subsequent criminal charges.
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Introduction
Substance dependence is a common medical problem
and is associated with criminal activity [1,2]. It is esti-
mated that nearly 6 million individuals are arrested each
year in the United States and that nearly one half meet
criteria for a substance use disorder, but most do not
receive treatment [3]. One of the goals of addiction
treatment is to reduce criminal activity. A number of
studies have reported a decrease in rates of crime when
opioid-dependent individuals are enrolled in opioid ago-
nist treatment, both when compared to the period prior
to enrollment [4-7], and when compared to those who
are not enrolled in opioid agonist treatment [8-10].
However, all of these studies involved subjects who were
on methadone maintenance therapy. While office-based
buprenorphine treatment has been shown to be an
effective treatment for opioid dependence [11], there are
no published studies of the effect of office-based bupre-
norphine maintenance therapy on criminal activity [12].
Given the prevalence of substance use in the criminal
justice population [13] and the current limited access to
pharmacologic treatment for opioid dependence, there is
a tremendous need for effective treatment; incarceration
may be an opportunity to initiate treatment for opioid
dependence and improve rates of recidivism [14,15].
Buprenorphine maintenance therapy may be more
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from prison, because of the greater flexibility of receiving
prescribed buprenorphine rather than attending a metha-
done maintenance program on a daily basis [16]. How-
ever, subjects with a criminal history may benefit from
the more intensive treatment and monitoring that a
methadone program offers. Moreover, a criminal history
may be associated with poorer treatment retention [17],
although one recent study found that a history of incar-
ceration was not associated with poorer outcomes in
office-based buprenorphine treatment [18].
The goal of this study is to determine the impact of
buprenorphine maintenance therapy in a primary care
setting on rates of criminal charges and to examine risk




The Comprehensive Care Practice is a primary care clinic
on the Johns Hopkins Bayview Medical Center campus
which is staffed by 5 internists, a nurse practitioner, and
3 internal medicine residents who share a panel of
patients. The practitioners provide general primary care,
with a focus of serving patients with HIV infection and/
or substance use disorders.
Visits for opioid dependence occur as routine primary
care visits. A more detailed description of this clinic’s
treatment practices has been published previously [19].
Briefly, there is no uniform protocol or dosing regimen,
with buprenorphine doses ranging from 2 to 32 mg, with
most patients on 8-16 mg daily. Induction occurs at
home or in the office and follow-up occurs weekly to
monthly, based on the provider’s discretion; patients are
usually seen more frequently early in treatment or when
there is continued substance use. Treatment is continued
or discontinued based on the provider’s discretion. The
practice does not provide any additional onsite psychoso-
cial services and patients are referred to community
resources.
Subjects
The study included all patients who had received at least
one prescription for sublingual formulation of buprenor-
phine from August 2003 to September 1, 2007.
Data collection
As part of a previously performed study [19], a database
of all patients who received at least one prescription for
buprenorphine during this period of time had already
been created. Data were collected retrospectively from
the patient medical records. Demographic information
recorded included age, gender, type of insurance and
employment status. Substance abuse history collected
included substances used and history of injection drug
use. We also collected data on recent (within 30 days)
drug treatment, including methadone and buprenorphine
maintenance. Also recorded were relevant comorbidities
(hepatitis C, HIV, chronic pain and chronic psychiatric
illness).
The time period after receiving the first prescription
was divided into twelve monthly blocks for the purposes
of outcomes analysis. Patients were considered to be in
treatment for each block in which they were prescribed
buprenorphine at any point. There was no fixed proto-
col for collection of urine drug tests, so for each month
in which the patient was receiving treatment, patients
were classified as “opioid-positive” or “opioid-negative”.
Patients were classified as “opioid-positive” if any of
their urine drug tests during that month were positive
for opioids (other than those prescribed), if they
reported using other non-prescribed opioids, or if a
urine drug test was not collected and their most recent
test was positive. Patients were classified as “opioid-
negative” if all urine drug tests collected during that
month were negative for opioids (other than those pre-
scribed), or if the provider decided not to collect a test
and their most recent one was negative.
We utilized the Maryland Judiciary Case Search web-
site http://casesearch.courts.state.md.us/inquiry/inquiry-
index.jsp to determine whether subjects had any criminal
charges and the number of cases filed against each sub-
ject. This database includes data on all criminal charges
in the state of Maryland since 1991. The database pro-
vides the defendant name, city and state, date of birth,
trial date, charges, and case disposition. We searched this
database by each patient’s name and birthdate, and
recorded whether the subject had ever had criminal
charges prior to initiating treatment. We tabulated the
total number and types of criminal cases two years prior
to the date of the first prescription for buprenorphine,
and for the two-year period of time after that date. We
counted cases as listed separately on the website, not
individual charges; we decided to do this because many
cases included multiple related charges (for example,
multiple charges of drug possession with separate charges
for possession of drug paraphernalia). We did not count
cases that were limited to motor vehicle charges, with the
exception of driving under the influence of alcohol. We
classified criminal cases as “drug cases” or “other"; “drug
cases” included any cases with charges of possession or
distribution of controlled dangerous substances (CDS).
Statistical analysis
Bivariate analysis was used to compare demographic fac-
tors and outcomes among subjects with and without
criminal charges in the two years after initiation of
treatment. We also used bivariate analysis to compare
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before and after initiation of treatment. We also com-
pared the number of criminal cases before and after
initiation of treatment among subjects who remained in
treatment at 12 months and those who were opioid
negative for 6 or more months. Chi-square tests were
used to analyze categorical variables and paired t tests
for continuous variables. Wilcoxon signed ranks and
Mann Whitney U tests were used to compare variables
that were not normally distributed. P values less than
0.05 were considered statistically significant. Multivariate
analysis was used to analyze factors associated with
criminal charges after initiation of treatment. Variables
with a p value < 0.1 were entered into the logistic
regression model; for factors that were highly co-linear
(Pearson’s correlation coefficient > 0.4), only one was
entered. Analysis was performed using PASW software
(version 18). This study was approved by the Johns
Hopkins Institutional Review Board.
Results
The study included 252 patients who had been given at
least one prescription for sublingual formulation of
buprenorphine from August 2003 to September 1, 2007.
Two subjects from the original cohort were not included
because they could not be identified due to gaps in
record-keeping.
The number of subjects with at least one criminal
charge in the two years after initiating treatment was 97
(38.4%). Table 1 provides demographic and outcome data
on subjects with and without criminal charges during
this period. A number of characteristics were associated
with criminal charges after enrollment in buprenorphine
maintenance therapy. Those who reported a history of
h e r o i na b u s ew e r em o r el i k e l yt oh a v eh a dc r i m i n a l
charges, while those who reported prescription drug
abuse were less likely to have been charged. Hepatitis C
virus (HCV) infection and injection drug use (IDU) were
also associated with criminal charges. Subjects with crim-
inal charges were less likely to have been receiving opioid
maintenance treatment within 30 days prior to initiating
treatment at this practice. All of the subjects with crim-
inal charges in the two years after initiating treatment
had prior criminal charges, compared to only 67.7% (p <
0.001) of those whom had no criminal charges after initi-
ating treatment; these subjects were also more likely to
have had charges in the 2 years prior to initiation of
treatment and had a significantly higher median number
of prior cases. Subjects with criminal charges in the two
years after starting treatment were less likely to achieve ≥
6 opioid-negative months; they were also less likely to
remain in treatment at 12 months, but this difference
was not statistically significant.
As shown in Table 2, there was a small decline in the
proportion of subjects with at least one criminal charge
in the two years before and after initiation of treatment,
but this was not statistically significant. Likewise, there
was no significant difference in the mean number of
criminal cases in the two years before and after enroll-
ment; before enrollment, there was a mean of 0.77 cases
per subject, compared to 0.70 cases after enrollment.
Among patients who remained in treatment at 12
months, there was no significant difference in the num-
ber of criminal cases before and after enrollment. How-
ever, among subjects who had ≥ 6 opioid-negative
months, there was a significant decline in the mean num-
ber of criminal cases.
Similar to the overall charges, there was no significant
difference in the proportion of subjects with at least one
drug charge. There was also no significant difference in
the mean number of drug cases before or after enroll-
ment. Likewise, there was no significant difference in
the mean number of drug cases among subjects who
remained in treatment at 12 months or among those
who achieved ≥ 6 opioid-negative months.
On multivariate analysis, charges in the past 2 years
was the strongest predictor of charges in the 2 years after
initiation of treatment, as shown in Table 3. Subjects
who were receiving opioid maintenance treatment within
30 days of initiating treatment at this practice were less
likely to have had subsequent charges. None of the other
factors was significantly associated with criminal charges
in the two years after initiation of treatment.
Discussion
In this cohort, enrollment in office-based buprenorphine
treatment did not seem to result in a significant decline
in criminal charges. There likewise was no significant dif-
ference in the proportion of subjects who had a drug
charge and no significant difference in the mean number
of drug cases. However, among the 46% of subjects who
were more successful in treatment, defined as ≥ 6 opioid-
negative months in the first year after initiation of treat-
ment, there was a significant decline in criminal cases.
T h i si st h ef i r s ts t u d yt oo u rk n o w l e d g et h a tl o o k sa t
the effect of office-based buprenorphine therapy on
criminal activity. Initiation of buprenorphine mainte-
nance therapy did not seem to result in a significant
decrease in criminal charges, including drug charges.
This is in contrast to several studies of subjects in
methadone maintenance treatment [4-7]. There are a
few possible reasons for these differences. One is that
we included all enrollees into our study, not just those
who remained in treatment; however, we did not see a
significant decline when limiting our analysis to those
who remained in treatment at one year. Another
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than self-report. Yet another difference is that subjects
in this primary care setting received less intensive moni-
toring than what is typically provided in methadone
maintenance programs. It is possible that these subjects
would do better in programs that monitor them closely
and provide more psychosocial support.
While treatment retention did not affect rates of crim-
inal charges in our cohort, those who had ≥ 6 opioid-nega-
tive months did have a significant decline in criminal
charges, suggesting that there was a subgroup in which
the treatment was associated with changes in criminal
behavior. Other studies have shown that larger reductions
in crime are associated with abstinence from opioids. For
example, a large study done in England, the National
Treatment Outcome Research Study (NTORS), used a
national database of convictions and found that there was
a significant decline in convictions at 5 years, and that this
was associated with reductions in heroin use [20].
Our findings may be relevant to the treatment of
recently-incarcerated individuals. Previous studies have
shown buprenorphine treatment to be effective in this
population and it may be better accepted than metha-
done maintenance [16]. However, if reduction in crim-
inal activity is a goal, then a referral to office-based
buprenophine treatment alone may not be sufficient.
This needs to be studied further and other strategies
developed to address the needs of this population.
One factor that may have attenuated the impact of
this treatment was that approximately one-fourth of the
Table 1 Comparison of subjects with and without criminal charges in the 2 years after initiation of office-based
buprenorphine treatment
Characteristic Criminal charges (N = 97) No criminal charges (N = 155) Χ
2, df P-value
a
Median Age (range) 40 (20-56) 41 (18-67) 0.770
b
Sex
Male 56 (57.7%) 86 (55.5%) 0.12, 1 0.726
Female 41 (42.3%) 69 (44.5%)
Insurance
Commercial 38 (39.2%) 66 (42.6%) 0.29, 1 0.593
Medicaid 36 (37.1%) 53 (34.2%) 0.22, 1 0.637
Medicare 19 (19.6%) 23 (14.8%) 0.04, 1 0.839
None 4 (4.1%) 4 (2.6%) 0.46, 1 0.497
Employment Status
Employed 38 (39.2%) 75 (48.4%) 2.07, 1 0.153
Unemployed 31 (32.0%) 43 (27.7%) 0.51, 1 0.457
Disabled 28 (28.9%) 37 (23.9%) 0.78, 1 0.378
Abused Substances
Heroin 90 (92.8%) 119 (76.8%) 10.81, 1 0.001
Opioid Rx 15 (15.5%) 57 (36.8%) 13.28, 1 < 0.001
Cocaine 58 (59.8%) 76 (49.0%) 0.003, 1 0.096
Alcohol 16 (16.5%) 26 (16.8%) 2.78,1 0.954
Benzodiazepines 8 (8.2%) 15 (9.7%) 0.15, 1 0.701
Recent opioid maintenance treatment 18 (18.6%) 50 (32.3%) 5.69, 1 0.017
IDU 67 (69.1%) 85 (54.8%) 5.05, 1 0.025
Co-morbidities
HIV 14 (14.4%) 22 (14.2%) 0.003, 1 0.958
HCV 58 (59.8%) 67 (43.2%) 6.55, 1 0.010
Psychiatric 102 (51.3%) 23 (43.4%) 1.60, 1 0.309
Chronic Pain 35 (17.6%) 11 (20.8%) 0.82, 1 0.596
Any prior criminal charges 97 (100%) 105 (67.7%) 39.04, 1 < 0.001
Median number of prior criminal cases (range) 9 (1-43) 1 (0-25) < 0.001
b
Any criminal charges in past 2 years 62 (63.9%) 46 (29.7%) 28.56, 1 < 0.001
≥ 6 opioid-negative mos. 34 (35.1%) 83 (53.5%) 8.21, 1 0.004
12 mos. in treatment 46 (47.4%) 93 (60.0%) 3.82, 1 0.051
IDU: injection drug use, HCV: hepatitis C infection, HIV: human immunodeficiency virus infection, df: degrees of freedom
a Pearson chi-square test unless otherwise indicated;
b Mann Whitney U test
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(methadone or buprenorphine) within 30 days of initiat-
ing treatment. While those who had recently been on
opioid maintenance treatment were less likely to have
subsequent criminal charges, when we excluded these
subjects from our analysis, we likewise did not find any
significant differences in number of criminal cases (total
or drug cases) before and after initiation of treatment
(data not shown).
A limitation of our study is that we looked only at
criminal charges; not all criminal activity leads to crim-
inal charges and not all charges are necessarily indica-
tive of criminal activity (i.e., some may have been
wrongly charged). On the other hand, criminal charges
are an objective measure and likely correlate with crim-
inal activity. These rates may have been affected by
changes in police or criminal justice policies; however,
Federal Bureau of Investigation statistics indicate that
there has been a decline in crime and arrest rates in
Maryland between 2001 and 2009 [21]; therefore, it is
unlikely that the absence of a significant decline was
due to more aggressive policing or enforcement.
Another limitation is that we only looked at criminal
charges recorded in Maryland, and could not include
crimes committed in other states. However, unlike many
other studies, we used an “intention-to-treat” model and
included everyone who had received at least one pre-
scription for buprenorphine, not just those who
remained in treatment.
In summary, our study suggests that a referral to
office-based buprenorphine treatment alone is not suffi-
cient to address criminal behavior among subjects with
opioid dependence and a history of criminal charges. It
is possible that some of these individuals may benefit
from more intensive treatment and monitoring than can
be provided in a primary care setting.
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Table 2 Overall charges and drug charges in the 2 years before and after initiation of buprenorphine treatment
2 years before treatment
initiation





Number of subjects with a charge (percentage) 108 (42.9%) 97 (38.5%) 0.22
a
Mean number of cases per subject (SD) 0.77 (1.21) 0.70 (1.15) 0.37
b
Mean number of cases among subjects in treatment for 12 months
(SD)
0.71 (1.25) 0.60 (1.08) 0.38
b
Mean number of cases among subjects opioid negative ≥ 6 months
(SD)
0.67 (1.19) 0.43 (0.78) 0.03
b
Drug charges
Number of subjects with a drug charge (percentage) 54 (21.4%) 65 (25.8%) 0.11
a
Mean number of drug cases per subject (SD) 0.31 (0.68) 0.35 (0.70) 0.46
b
Mean number of drug cases among subjects in treatment for 12
months (SD)
0.30 (0.71) 0.34 (0.74) 0.60
b
Mean number of drug cases among subjects opioid negative ≥ 6
months (SD)
0.28 (0.72) 0.21 (0.48) 0.27
b
SD-standard deviation
a Pearson chi-square test;
b Wilcoxon signed ranks test
Table 3 Multivariate analysis of factors associated with criminal charges in the 2 years after initiation of office-based
buprenorphine treatment
Factor Adjusted Odds Ratio (95% confidence interval) P value
a
Recent charges (past 2 years) 3.893 (2.216-6.839) < 0.001
Recent opioid maintenance 0.515 (0.265-0.998) 0.049
≥ 6 months opioid negative 0.597 (0.335-1.063) 0.080
Heroin abuse 2.479 (0.897-6.994) 0.086
Cocaine abuse 1.459 (0.804-2.648) 0.214
Injection drug use 1.186 (0.618-2.275) 0.609
The following factors were not included in the multivariate analysis due to a high correlation with another factor (indicated in parenthesis): any prior charges
(recent charges), remaining in treatment at 12 months (≥ 6 months opioid negative), prescription opioid abuse (heroin abuse), hepatitis C (injection drug use).
a P values calculated by Wald chi-square tests in a logistic regression model; degrees of freedom = 1 for each
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